• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy
    Subscribe to $TGTX

    TG Therapeutics Inc.

    Subscribe to $TGTX
    $TGTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its therapeutic product candidates include Ublituximab, an investigational glycoengineered monoclonal antibody for the treatment of B-cell non-hodgkin lymphoma, chronic lymphocytic leukemia (CLL), and relapsing forms of multiple sclerosis; and Umbralisib, an oral inhibitor of PI3K-delta and CK1-epsilon for the treatment of CLL, marginal zone lymphoma, and follicular lymphoma. The company also develops Cosibelimab, a human monoclonal antibody of IgG1 subtype that binds to programmed death-ligand 1 (PD-L1) and blocks its interactions with PD-1 and B7.1 receptors; TG-1701 is an orally available and covalently-bound Bruton's tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK compared to ibrutinib in in vitro kinase screening; and TG-1801, a bispecific CD47 and CD19 antibody. In addition, it has various licensed preclinical programs for BET, interleukin-1 receptor associated kinase-4, and GITR; and collaboration agreements with Checkpoint Therapeutics, Inc., Jiangsu Hengrui Medicine Co., Novimmune SA, Ligand Pharmaceuticals Incorporated, and Jubilant Biosys. The company has strategic alliances with LFB Biotechnologies S.A.S; GTC Biotherapeutics; LFB/GTC LLC; Ildong Pharmaceutical Co. Ltd.; and Rhizen Pharmaceuticals, S A. The company is headquartered in New York, New York.

    IPO Year:

    Exchange: NASDAQ

    Website: tgtherapeutics.com

    Peers

    $APLT
    $CKPT
    $FATE
    $GTHX
    $TPTX

    Recent Analyst Ratings for TG Therapeutics Inc.

    DatePrice TargetRatingAnalyst
    10/29/2024$50.00Buy
    TD Cowen
    8/2/2023$16.00 → $12.00Sell → Neutral
    Goldman
    6/26/2023$55.00 → $40.00Buy
    Jefferies
    5/20/2022$5.00Underperform
    BofA Securities
    2/23/2022$49.00 → $35.00Buy
    B. Riley Securities
    1/28/2022$70.00 → $68.00Buy
    HC Wainwright & Co.
    1/24/2022$75.00 → $70.00Buy
    HC Wainwright & Co.
    12/1/2021$55.00 → $36.00Outperform
    Evercore ISI Group
    12/1/2021$26.00 → $13.00Sell
    Goldman Sachs
    12/1/2021$84.00 → $75.00Buy
    HC Wainwright & Co.
    See more ratings

    TG Therapeutics Inc. Press Releases

    Fastest customizable press release news feed in the world

    See more
    • TG Therapeutics Reports First Quarter 2025 Financial Results and Raises BRIUMVI Full Year Revenue Guidance

      First quarter 2025 BRIUMVI U.S. net revenue of $119.7 million Raises full year 2025 global net revenue target to approximately $575 million and raises full year BRIUMVI U.S. net revenue target to approximately $560 million Conference call to be held today, Monday, May 5, 2025, at 8:30 AM ET    NEW YORK, May 05, 2025 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ:TGTX) (the Company or TG Therapeutics) today announced its financial results for the first quarter of 2025, along with recent company developments and provided an update on 2025 revenue guidance. Michael S. Weiss, the Company's Chairman and Chief Executive Officer, stated, "2025 is off to a strong start, and I'm incredibly

      5/5/25 7:00:00 AM ET
      $TGTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • TG Therapeutics to Host Conference Call on First Quarter 2025 Financial Results and Business Update

      NEW YORK, April 30, 2025 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ:TGTX), today announced that a conference call will be held, Monday, May 5, 2025, at 8:30 AM ET to discuss results for the first quarter of 2025 and provide a business outlook for the remainder of 2025. Michael S. Weiss, Chairman and Chief Executive Officer, will host the call. In order to participate in the conference call, please call 1-877-407-8029 (U.S.), 1-201-689-8029 (outside the U.S.), Conference Title: TG Therapeutics Earnings Call. A live webcast of this presentation will be available on the Events page, located within the Investors & Media section, of the Company's website at www.tgtherapeutics.com. An au

      4/30/25 7:30:00 AM ET
      $TGTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • TG Therapeutics Announces Data Presentations for BRIUMVI in Multiple Sclerosis at the American Academy of Neurology 2025 Annual Meeting

      NEW YORK, April 08, 2025 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ:TGTX), today announced the presentation of data highlighting BRIUMVI® (ublituximab-xiiy) in patients with relapsing forms of multiple sclerosis (RMS), at the American Academy of Neurology 2025 annual meeting. Links to each presentation are included below. Michael S. Weiss, Chief Executive Officer and Chairman of TG Therapeutics stated, "We were pleased to share three presentations yesterday which we believe demonstrate our continued commitment to improving the patient experience and understanding the long term and real-world profile of BRIUMVI." Mr. Weiss continued, "The results of the retrospective ENAMOR surv

      4/8/25 7:30:00 AM ET
      $TGTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • TG Therapeutics Announces Two Publications Highlighting BRIUMVI in Medical Journals

      NEW YORK, April 07, 2025 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ:TGTX) today announced the publication of two journal articles one describing the evolution of CD20 treatments for multiple sclerosis (MS) and the other detailing the experience of seven individuals with MS who switched to BRIUMVI® (ublituximab-xiiy) from a different anti-CD20 monoclonal antibody therapy due to efficacy or tolerability concerns. Details of the publications are provided below. Michael S. Weiss, the Company's Executive Chairman and Chief Executive Officer stated, "We are encouraged by these publications, and believe taken together they may provide a rationale for switching patients within the CD20 cla

      4/7/25 7:30:00 AM ET
      $TGTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • TG Therapeutics Announces Schedule of Data Presentations for BRIUMVI® (ublituximab) in Multiple Sclerosis at the American Academy of Neurology 2025 Annual Meeting

      NEW YORK, March 07, 2025 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ:TGTX), today announced the upcoming schedule of presentations highlighting BRIUMVI® (ublituximab-xiiy) data in patients with relapsing forms of multiple sclerosis (RMS), at the American Academy of Neurology 2025 annual meeting, being held April 5 - 9, 2025, in San Diego, California. Abstracts are now available online and can be accessed on the AAN meeting website at https://www.aan.com/events/annual-meeting-abstracts. Details of the upcoming presentations are outlined below. TG PRESENTATIONS: Poster Presentation Title: No Association Between Decreases in Serum Immunoglobulin (Ig) Levels

      3/7/25 7:30:00 AM ET
      $TGTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • TG Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2024 Financial Results

      Fourth quarter and full year 2024 BRIUMVI U.S. net revenue of $103.6 million and $310 million, respectively Target guidance of approximately $540 million in total global revenue for 2025 Conference call to be held today, March 3, 2025, at 8:30 AM ET NEW YORK, March 03, 2025 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ:TGTX) (the Company or TG Therapeutics) today announced its financial results for the fourth quarter and full year ended December 31, 2024, along with recent company developments. Michael S. Weiss, the Company's Chairman and Chief Executive Officer, stated,

      3/3/25 7:00:00 AM ET
      $TGTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • TG Therapeutics Announces Presentation of Data for BRIUMVI® in Multiple Sclerosis at the Americas Committee for Treatment and Research in Multiple Sclerosis Annual Forum

      NEW YORK, Feb. 27, 2025 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ:TGTX), today announced the presentation of data from the ULTIMATE I & II Phase 3 trials and the ENHANCE Phase 3b trial evaluating BRIUMVI® (ublituximab-xiiy) in patients with relapsing forms of multiple sclerosis (RMS), at the Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) annual forum, being held in West Palm Beach, Florida. Links to each presentation are included below. Michael S. Weiss, Chief Executive Officer and Chairman of TG Therapeutics stated, "We are pleased to share data at this year's ACTRIMS annual meeting including updated data from the ENHANCE trial, which aims to ex

      2/27/25 7:30:00 AM ET
      $TGTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • TG Therapeutics to Host Conference Call on Fourth Quarter and Full Year 2024 Financial Results and Business Update

      NEW YORK, Feb. 26, 2025 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ:TGTX), today announced that a conference call will be held, Monday, March 3, 2025, at 8:30 AM ET to discuss results for the fourth quarter and full year 2024 and to provide a business outlook for 2025. Michael S. Weiss, Chairman and Chief Executive Officer, will host the call. In order to participate in the conference call, please call 1-877-407-8029 (U.S.), 1-201-689-8029 (outside the U.S.), Conference Title: TG Therapeutics Earnings Call. A live webcast of this presentation will be available on the Events page, located within the Investors & Media section, of the Company's website at www.tgtherapeutics.com. An a

      2/26/25 7:30:00 AM ET
      $TGTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • TG Therapeutics Announces Schedule of Data Presentations for BRIUMVI® (ublituximab) in Multiple Sclerosis at the Americas Committee for Treatment and Research in Multiple Sclerosis Annual Forum

      NEW YORK, Feb. 18, 2025 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ:TGTX), today announced the schedule of presentations highlighting data from the ULTIMATE I & II Phase 3 trials and the ENHANCE Phase 3b trial evaluating BRIUMVI® (ublituximab-xiiy) in patients with relapsing forms of multiple sclerosis (RMS) to be presented at the upcoming Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) annual forum, being held February 27 – March 1, 2025, in West Palm Beach, Florida. Abstracts are now available online and can be accessed on the ACTRIMS meeting website at www.forum.actrims.org. Details of the upcoming presentations are outlined below. TG PRESENTATIONS:P

      2/18/25 7:30:00 AM ET
      $TGTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • TG Therapeutics Provides Preliminary Fourth Quarter and Full Year 2024 Net Revenue and 2025 Anticipated Development Milestones

      Preliminary U.S. BRIUMVI fourth quarter and full year 2024 net product revenue of $103.6 million and $310 million, respectively Full Year 2025 target total global revenue of approximately $540 million, including BRIUMVI U.S. net product revenue of approximately $525 million NEW YORK, Jan. 14, 2025 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ:TGTX), yesterday announced preliminary U.S. net product revenue for BRIUMVI® for the fourth quarter and full year ended December 31, 2024 (unaudited), as well as financial guidance and development milestones for 2025, during a preannounced presentation at the 43rd Annual J.P Morgan Healthcare Conference. An audio repl

      1/14/25 7:00:00 AM ET
      $TGTX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    TG Therapeutics Inc. FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    See more
    • FDA Approval for BRIUMVI issued to TG THERAPEUTICS, INC

      Submission status for TG THERAPEUTICS, INC's drug BRIUMVI (SUPPL-11) with active ingredient UBLITUXIMAB-XIIY has changed to 'Approval' on 10/30/2024. Application Category: BLA, Application Number: 761238, Application Classification:

      10/31/24 4:38:40 AM ET
      $TGTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • FDA Approval for BRIUMVI issued to TG THERAPEUTICS, INC

      Submission status for TG THERAPEUTICS, INC's drug BRIUMVI (ORIG-1) with active ingredient UBLITUXIMAB has changed to 'Approval' on 12/28/2022. Application Category: BLA, Application Number: 761238, Application Classification:

      12/28/22 12:54:09 PM ET
      $TGTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • FDA Approval for UKONIQ

      Submission status for TG THERAPEUTICS INC's drug UKONIQ (ORIG-2) with active ingredient UMBRALISIB TOSYLATE has changed to 'Approval' on 02/05/2021. Application Category: NDA, Application Number: 213176, Application Classification: Type 1 - New Molecular Entity

      2/9/21 12:05:59 PM ET
      $TGTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • FDA Approval for UKONIQ

      Submission status for TG THERAPEUTICS INC's drug UKONIQ (ORIG-1) with active ingredient UMBRALISIB TOSYLATE has changed to 'Approval' on 02/05/2021. Application Category: NDA, Application Number: 213176, Application Classification: Type 1 - New Molecular Entity

      2/9/21 12:05:59 PM ET
      $TGTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • FDA Approval for UKONIQ

      Submission status for TG THERAPEUTICS INC's drug UKONIQ (ORIG-2) with active ingredient UMBRALISIB has changed to 'Approval' on 02/05/2021. Application Category: NDA, Application Number: 213176, Application Classification: Type 1 - New Molecular Entity

      2/5/21 1:35:26 PM ET
      $TGTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • FDA Approval for UKONIQ

      Submission status for TG THERAPEUTICS INC's drug UKONIQ (ORIG-1) with active ingredient UMBRALISIB has changed to 'Approval' on 02/05/2021. Application Category: NDA, Application Number: 213176, Application Classification: Type 1 - New Molecular Entity

      2/5/21 1:35:26 PM ET
      $TGTX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    TG Therapeutics Inc. Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Hume Daniel gifted 62,459 shares, decreasing direct ownership by 26% to 178,030 units (SEC Form 4)

      4 - TG THERAPEUTICS, INC. (0001001316) (Issuer)

      3/18/25 5:01:41 PM ET
      $TGTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Charney Laurence N gifted 6,000 shares, decreasing direct ownership by 3% to 201,479 units (SEC Form 4)

      4 - TG THERAPEUTICS, INC. (0001001316) (Issuer)

      3/11/25 5:00:42 PM ET
      $TGTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • CEO Weiss Michael S was granted 750,000 shares, increasing direct ownership by 6% to 13,824,929 units (SEC Form 4)

      4 - TG THERAPEUTICS, INC. (0001001316) (Issuer)

      1/30/25 5:17:24 PM ET
      $TGTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • CFO Power Sean A was granted 87,500 shares, increasing direct ownership by 14% to 708,111 units (SEC Form 4)

      4 - TG THERAPEUTICS, INC. (0001001316) (Issuer)

      1/30/25 5:15:48 PM ET
      $TGTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • CFO Power Sean A sold $629,382 worth of shares (21,358 units at $29.47), decreasing direct ownership by 3% to 660,611 units (SEC Form 4)

      4 - TG THERAPEUTICS, INC. (0001001316) (Issuer)

      1/7/25 6:01:15 PM ET
      $TGTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Lonial Sagar sold $152,200 worth of shares (5,000 units at $30.44), decreasing direct ownership by 5% to 100,195 units (SEC Form 4)

      4 - TG THERAPEUTICS, INC. (0001001316) (Issuer)

      11/12/24 5:02:38 PM ET
      $TGTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Charney Laurence N sold $754,875 worth of shares (25,000 units at $30.20) and gifted 5,000 shares, decreasing direct ownership by 13% to 207,479 units (SEC Form 4)

      4 - TG THERAPEUTICS, INC. (0001001316) (Issuer)

      11/12/24 5:01:39 PM ET
      $TGTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Echelard Yann sold $489,600 worth of shares (20,000 units at $24.48), decreasing direct ownership by 8% to 224,098 units (SEC Form 4)

      4 - TG THERAPEUTICS, INC. (0001001316) (Issuer)

      11/7/24 4:35:48 PM ET
      $TGTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Lonial Sagar sold $432,889 worth of shares (25,933 units at $16.69) and was granted 22,250 shares, decreasing direct ownership by 3% to 105,195 units (SEC Form 4)

      4 - TG THERAPEUTICS, INC. (0001001316) (Issuer)

      6/20/24 6:07:53 PM ET
      $TGTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Hume Daniel was granted 22,250 shares, increasing direct ownership by 10% to 240,489 units (SEC Form 4)

      4 - TG THERAPEUTICS, INC. (0001001316) (Issuer)

      6/20/24 6:07:09 PM ET
      $TGTX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    TG Therapeutics Inc. SEC Filings

    See more
    • SEC Form 10-Q filed by TG Therapeutics Inc.

      10-Q - TG THERAPEUTICS, INC. (0001001316) (Filer)

      5/9/25 4:31:06 PM ET
      $TGTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • TG Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - TG THERAPEUTICS, INC. (0001001316) (Filer)

      5/5/25 7:31:59 AM ET
      $TGTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form DEFA14A filed by TG Therapeutics Inc.

      DEFA14A - TG THERAPEUTICS, INC. (0001001316) (Filer)

      4/30/25 4:18:47 PM ET
      $TGTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form DEF 14A filed by TG Therapeutics Inc.

      DEF 14A - TG THERAPEUTICS, INC. (0001001316) (Filer)

      4/30/25 4:18:13 PM ET
      $TGTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SCHEDULE 13G/A filed by TG Therapeutics Inc.

      SCHEDULE 13G/A - TG THERAPEUTICS, INC. (0001001316) (Subject)

      4/30/25 12:45:21 PM ET
      $TGTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form PRE 14A filed by TG Therapeutics Inc.

      PRE 14A - TG THERAPEUTICS, INC. (0001001316) (Filer)

      4/18/25 4:13:50 PM ET
      $TGTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 10-K filed by TG Therapeutics Inc.

      10-K - TG THERAPEUTICS, INC. (0001001316) (Filer)

      3/3/25 4:02:11 PM ET
      $TGTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • TG Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - TG THERAPEUTICS, INC. (0001001316) (Filer)

      3/3/25 7:19:26 AM ET
      $TGTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • TG Therapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - TG THERAPEUTICS, INC. (0001001316) (Filer)

      1/14/25 4:02:03 PM ET
      $TGTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SCHEDULE 13G/A filed by TG Therapeutics Inc.

      SCHEDULE 13G/A - TG THERAPEUTICS, INC. (0001001316) (Subject)

      1/8/25 11:29:53 AM ET
      $TGTX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    TG Therapeutics Inc. Leadership Updates

    Live Leadership Updates

    See more
    • Palantir Technologies, Dell Technologies, and Erie Indemnity Set to Join S&P 500; Others to Join S&P MidCap 400 and S&P SmallCap 600

      NEW YORK, Sept. 6, 2024 /PRNewswire/ -- S&P Dow Jones Indices ("S&P DJI") will make the following changes to the S&P 500, S&P MidCap 400, and S&P SmallCap 600 indices effective prior to the open of trading on Monday, September 23, to coincide with the quarterly rebalance. The changes ensure each index is more representative of its market capitalization range. All companies being added to the S&P 500 are more representative of the large-cap market space, all companies being added to the S&P MidCap 400 are more representative of the mid-cap market space, and all companies being added to the S&P SmallCap 600 are more representative of the small-cap market space. The companies being removed from

      9/6/24 6:43:00 PM ET
      $AAL
      $ADMA
      $ADNT
      $AMCX
      Air Freight/Delivery Services
      Consumer Discretionary
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    TG Therapeutics Inc. Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by TG Therapeutics Inc.

      SC 13G/A - TG THERAPEUTICS, INC. (0001001316) (Subject)

      11/14/24 7:45:34 PM ET
      $TGTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by TG Therapeutics Inc. (Amendment)

      SC 13G/A - TG THERAPEUTICS, INC. (0001001316) (Subject)

      2/14/24 3:30:53 PM ET
      $TGTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by TG Therapeutics Inc. (Amendment)

      SC 13G/A - TG THERAPEUTICS, INC. (0001001316) (Subject)

      1/25/24 11:29:01 AM ET
      $TGTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by TG Therapeutics Inc.

      SC 13G - TG THERAPEUTICS, INC. (0001001316) (Subject)

      4/3/23 8:00:16 AM ET
      $TGTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by TG Therapeutics Inc. (Amendment)

      SC 13G/A - TG THERAPEUTICS, INC. (0001001316) (Subject)

      2/9/23 12:39:51 PM ET
      $TGTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by TG Therapeutics Inc. (Amendment)

      SC 13G/A - TG THERAPEUTICS, INC. (0001001316) (Subject)

      2/9/23 11:35:14 AM ET
      $TGTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by TG Therapeutics Inc. (Amendment)

      SC 13G/A - TG THERAPEUTICS, INC. (0001001316) (Subject)

      2/3/23 4:27:14 PM ET
      $TGTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by TG Therapeutics Inc. (Amendment)

      SC 13G/A - TG THERAPEUTICS, INC. (0001001316) (Subject)

      10/11/22 10:07:19 AM ET
      $TGTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by TG Therapeutics Inc. (Amendment)

      SC 13G/A - TG THERAPEUTICS, INC. (0001001316) (Subject)

      7/11/22 8:49:54 AM ET
      $TGTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by TG Therapeutics Inc. (Amendment)

      SC 13G/A - TG THERAPEUTICS, INC. (0001001316) (Subject)

      2/9/22 10:01:24 AM ET
      $TGTX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    TG Therapeutics Inc. Financials

    Live finance-specific insights

    See more
    • TG Therapeutics Reports First Quarter 2025 Financial Results and Raises BRIUMVI Full Year Revenue Guidance

      First quarter 2025 BRIUMVI U.S. net revenue of $119.7 million Raises full year 2025 global net revenue target to approximately $575 million and raises full year BRIUMVI U.S. net revenue target to approximately $560 million Conference call to be held today, Monday, May 5, 2025, at 8:30 AM ET    NEW YORK, May 05, 2025 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ:TGTX) (the Company or TG Therapeutics) today announced its financial results for the first quarter of 2025, along with recent company developments and provided an update on 2025 revenue guidance. Michael S. Weiss, the Company's Chairman and Chief Executive Officer, stated, "2025 is off to a strong start, and I'm incredibly

      5/5/25 7:00:00 AM ET
      $TGTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • TG Therapeutics to Host Conference Call on First Quarter 2025 Financial Results and Business Update

      NEW YORK, April 30, 2025 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ:TGTX), today announced that a conference call will be held, Monday, May 5, 2025, at 8:30 AM ET to discuss results for the first quarter of 2025 and provide a business outlook for the remainder of 2025. Michael S. Weiss, Chairman and Chief Executive Officer, will host the call. In order to participate in the conference call, please call 1-877-407-8029 (U.S.), 1-201-689-8029 (outside the U.S.), Conference Title: TG Therapeutics Earnings Call. A live webcast of this presentation will be available on the Events page, located within the Investors & Media section, of the Company's website at www.tgtherapeutics.com. An au

      4/30/25 7:30:00 AM ET
      $TGTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • TG Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2024 Financial Results

      Fourth quarter and full year 2024 BRIUMVI U.S. net revenue of $103.6 million and $310 million, respectively Target guidance of approximately $540 million in total global revenue for 2025 Conference call to be held today, March 3, 2025, at 8:30 AM ET NEW YORK, March 03, 2025 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ:TGTX) (the Company or TG Therapeutics) today announced its financial results for the fourth quarter and full year ended December 31, 2024, along with recent company developments. Michael S. Weiss, the Company's Chairman and Chief Executive Officer, stated,

      3/3/25 7:00:00 AM ET
      $TGTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • TG Therapeutics to Host Conference Call on Fourth Quarter and Full Year 2024 Financial Results and Business Update

      NEW YORK, Feb. 26, 2025 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ:TGTX), today announced that a conference call will be held, Monday, March 3, 2025, at 8:30 AM ET to discuss results for the fourth quarter and full year 2024 and to provide a business outlook for 2025. Michael S. Weiss, Chairman and Chief Executive Officer, will host the call. In order to participate in the conference call, please call 1-877-407-8029 (U.S.), 1-201-689-8029 (outside the U.S.), Conference Title: TG Therapeutics Earnings Call. A live webcast of this presentation will be available on the Events page, located within the Investors & Media section, of the Company's website at www.tgtherapeutics.com. An a

      2/26/25 7:30:00 AM ET
      $TGTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • TG Therapeutics Reports Third Quarter 2024 Financial Results and Raises BRIUMVI® (ublituximab-xiiy) Full Year Revenue Guidance

      Third quarter 2024 U.S. BRIUMVI net revenue of $83.3 million Raises full year 2024 U.S. BRIUMVI net revenue target to $300 - $305 million Conference call to be held today, November 4, 2024, at 8:30 AM ET    NEW YORK, Nov. 04, 2024 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ:TGTX) (the Company or TG Therapeutics) today announced its financial results for the third quarter of 2024, along with recent company developments and provided an update on 2024 revenue guidance. Michael S. Weiss, the Company's Chairman and Chief Executive Officer stated, "The positive feedback and uptake of BRIUMVI in the marketplace continues to outpace our expectations and we are excited to

      11/4/24 7:00:00 AM ET
      $TGTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • TG Therapeutics to Host Conference Call on Third Quarter 2024 Financial Results and Business Update

      NEW YORK, Nov. 01, 2024 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ:TGTX), today announced that a conference call will be held, Monday November 4, 2024, at 8:30 AM ET to discuss results for the third quarter of 2024 and provide a business outlook for the remainder of the year. Michael S. Weiss, Chairman and Chief Executive Officer, will host the call. In order to participate in the conference call, please call 1-877-407-8029 (U.S.), 1-201-689-8029 (outside the U.S.), Conference Title: TG Therapeutics Earnings Call. A live webcast of this presentation will be available on the Events page, located within the Investors & Media section, of the Company's website at www.tgtherapeutics.com

      11/1/24 8:06:02 AM ET
      $TGTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • TG Therapeutics Reports Second Quarter 2024 Financial Results and Raises BRIUMVI® (ublituximab-xiiy) Full Year Revenue Guidance

      Second quarter 2024 U.S. BRIUMVI net revenue of $72.6 million Raising full year 2024 U.S. BRIUMVI net revenue target to approximately $290 - $300 million Cash flow positive for second quarter 2024 Establishes $250 million credit facility to repay existing debt and to buy back up to $100 million of common stock under a share repurchase program Initiated phase 1 study in RMS patients for subcutaneous ublituximab and received FDA IND clearance to study azer-cel (allogeneic CD19 CAR-T) in patients with progressive MS Conference call to be held today, August 6, 2024, at 8:30 AM ET NEW YORK, Aug. 06, 2024 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ:TGTX) (the Company or TG Therape

      8/6/24 7:00:00 AM ET
      $TGTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • TG Therapeutics to Host Conference Call on Second Quarter 2024 Financial Results and Business Update

      NEW YORK, Aug. 05, 2024 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ:TGTX), today announced that a conference call will be held, Tuesday August 6, 2024 at 8:30 AM ET to discuss results for the second quarter of 2024 and provide a business outlook for 2024. Michael S. Weiss, Chairman and Chief Executive Officer, will host the call. In order to participate in the conference call, please call 1-877-407-8029 (U.S.), 1-201-689-8029 (outside the U.S.), Conference Title: TG Therapeutics Second Quarter Earnings Call. A live webcast of this presentation will be available on the Events page, located within the Investors & Media section, of the Company's website at www.tgtherapeutics.com. An au

      8/5/24 7:30:00 AM ET
      $TGTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • TG Therapeutics Provides Business Update and Reports First Quarter 2024 Financial Results

      First quarter 2024 BRIUMVI U.S. net revenue of $50.5 million, representing >25% quarter over quarter growth Total revenue for Q1 2024 of $63.5 million, including a $12.5 million milestone payment for BRIUMVI launch in first EU country New BRIUMVI prescriptions to the TG hub of over 1,250 for Q1 2024, representing >25% growth quarter over quarter Conference call to be held today, May 1, 2024, at 8:30 AM ET NEW YORK, May 01, 2024 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ:TGTX) (the Company or TG Therapeutics) today announced its financial results for the first quarter of 2024, along with recent company developments. Michael S. Weiss, the Company's Chairman and Chief Executive O

      5/1/24 7:00:00 AM ET
      $TGTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • TG Therapeutics to Host Conference Call on First Quarter 2024 Financial Results and Business Update

      NEW YORK, April 30, 2024 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ:TGTX), today announced that a conference call will be held tomorrow, Wednesday, May 1, 2024, at 8:30 AM ET to discuss results for the first quarter of 2024 and provide a business outlook for 2024. Michael S. Weiss, Chairman and Chief Executive Officer, will host the call. In order to participate in the conference call, please call 1-877-407-8029 (U.S.), 1-201-689-8029 (outside the U.S.), Conference Title: TG Therapeutics First Quarter Update Call. A live webcast of this presentation will be available on the Events page, located within the Investors & Media section, of the Company's website at www.tgtherapeutics.com

      4/30/24 4:55:29 PM ET
      $TGTX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    TG Therapeutics Inc. Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • TD Cowen initiated coverage on TG Therapeutics with a new price target

      TD Cowen initiated coverage of TG Therapeutics with a rating of Buy and set a new price target of $50.00

      10/29/24 6:30:43 AM ET
      $TGTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • TG Therapeutics upgraded by Goldman with a new price target

      Goldman upgraded TG Therapeutics from Sell to Neutral and set a new price target of $12.00 from $16.00 previously

      8/2/23 8:51:11 AM ET
      $TGTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Jefferies resumed coverage on TG Therapeutics with a new price target

      Jefferies resumed coverage of TG Therapeutics with a rating of Buy and set a new price target of $40.00 from $55.00 previously

      6/26/23 9:08:22 AM ET
      $TGTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • BofA Securities initiated coverage on TG Therapeutics with a new price target

      BofA Securities initiated coverage of TG Therapeutics with a rating of Underperform and set a new price target of $5.00

      5/20/22 7:27:01 AM ET
      $TGTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • B. Riley Securities reiterated coverage on TG Therapeutics with a new price target

      B. Riley Securities reiterated coverage of TG Therapeutics with a rating of Buy and set a new price target of $35.00 from $49.00 previously

      2/23/22 10:54:09 AM ET
      $TGTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • HC Wainwright & Co. reiterated coverage on TG Therapeutics with a new price target

      HC Wainwright & Co. reiterated coverage of TG Therapeutics with a rating of Buy and set a new price target of $68.00 from $70.00 previously

      1/28/22 6:14:15 AM ET
      $TGTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • HC Wainwright & Co. reiterated coverage on TG Therapeutics with a new price target

      HC Wainwright & Co. reiterated coverage of TG Therapeutics with a rating of Buy and set a new price target of $70.00 from $75.00 previously

      1/24/22 4:29:06 AM ET
      $TGTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Evercore ISI Group reiterated coverage on TG Therapeutics with a new price target

      Evercore ISI Group reiterated coverage of TG Therapeutics with a rating of Outperform and set a new price target of $36.00 from $55.00 previously

      12/1/21 9:22:12 AM ET
      $TGTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Goldman Sachs reiterated coverage on TG Therapeutics with a new price target

      Goldman Sachs reiterated coverage of TG Therapeutics with a rating of Sell and set a new price target of $13.00 from $26.00 previously

      12/1/21 7:32:29 AM ET
      $TGTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • HC Wainwright & Co. reiterated coverage on TG Therapeutics with a new price target

      HC Wainwright & Co. reiterated coverage of TG Therapeutics with a rating of Buy and set a new price target of $75.00 from $84.00 previously

      12/1/21 6:26:17 AM ET
      $TGTX
      Biotechnology: Pharmaceutical Preparations
      Health Care